SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

☐ Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person *	2. Issuer Name **and** Ticker or Trading Symbol	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)
Kelderman Kim	BIO-TECHNE Corp [TECH]	X Director — 10% Owner
(Last) (First) (Middle)	3. Date of Earliest Transaction (Month/Day/Year)	X Officer (give title below) — Other (specify below)
614 MCKINLEY PLACE NE	08/15/2026	Chief Executive Officer
(Street)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line)
MINNEAPOLIS MN 55413	08/18/2026	X Form filed by One Reporting Person
(City) (State) (Zip)		Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	08/15/2026		M		21,736	A	$0	93,849	D	
Common Stock	08/15/2026		F		10,955	D	$72.4	82,894	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Performance Stock Options (Right to Buy)	$84.61	08/15/2026		D			22,044	(1)	(1)	Common Stock	22,044	$0	1,837	D	
Performance Stock Options (Right to Buy)	$68.54	08/15/2026		D			23,949	(2)	(2)	Common Stock	23,949	$0	1,996	D	
Performance Restricted Stock Units	(3)	08/15/2026		M			683	(4)	(4)	Common Stock	683	$0	8,190	D	
Performance Restricted Stock Units	(3)	08/15/2026		D			8,190	(4)	(4)	Common Stock	8,190	$0	0	D	
Performance Restricted Stock Units	(3)	08/15/2026		M			725	(5)	(5)	Common Stock	725	$0	8,698	D	
Performance Restricted Stock Units	(3)	08/15/2026		D			8,698	(5)	(5)	Common Stock	8,698	$0	0	D	

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Restricted Stock Units	(3)	08/15/2026		M			8,543	(6)	(6)	Common Stock	8,543	$0	8,544	D	
Restricted Stock Units	(3)	08/15/2026		M			11,785	(7)	(7)	Common Stock	11,785	$0	23,569	D	

Explanation of Responses:

1. On 8/15/2026, the Board of Directors authorized discretionary vesting for 1,837 performance options. The remainder of the performance options were forfeited.
2. On 8/15/2026, the Board of Directors authorized discretionary vesting for 1,996 performance options. The remainder of the performance options were forfeited.
3. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
4. On 8/15/2026, the Board of Directors authorized discretionary vesting for 683 performance RSUs. The remainder of the performance RSUs were forfeited.
5. On 8/15/2026, the Board of Directors authorized discretionary vesting for 725 performance RSUs. The remainder of the performance RSUs were forfeited.
6. 8,543 restricted stock units vest on 8/15/2026, and 8,544 restricted stock units vest on 8/15/2027.
7. 11,785 restricted stock units vest on each of 8/15/2026 and 8/15/2027, and 11,784 restricted stock units vest on 8/15/2028.

/s/ Andrew Nick, Attorney-in-Fact for Kim Kelderman pursuant to Power of Attorney previously filed. 11/02/2026

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, *see* Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.